Caldwell Trust Co Has $1.30 Million Holdings in Astrazeneca Plc $AZN

Caldwell Trust Co lessened its position in Astrazeneca Plc (NYSE:AZN) by 39.9% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 6,618 shares of the company’s stock after selling 4,402 shares during the quarter. Caldwell Trust Co’s holdings in Astrazeneca were worth $1,305,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Triumph Capital Management acquired a new stake in Astrazeneca during the 3rd quarter valued at $25,000. MV Capital Management Inc. acquired a new stake in shares of Astrazeneca in the fourth quarter worth $26,000. Bangor Savings Bank boosted its position in shares of Astrazeneca by 102.7% in the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock worth $28,000 after buying an additional 154 shares during the period. Eagle Bay Advisors LLC purchased a new position in shares of Astrazeneca during the fourth quarter valued at $30,000. Finally, YANKCOM Partnership purchased a new position in shares of Astrazeneca during the fourth quarter valued at $31,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

AZN has been the topic of several recent analyst reports. Barclays reissued a “buy” rating on shares of Astrazeneca in a research report on Monday, June 1st. TD Cowen reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Wednesday, March 18th. Sanford C. Bernstein reiterated a “buy” rating on shares of Astrazeneca in a report on Monday, May 4th. Jefferies Financial Group reissued a “buy” rating on shares of Astrazeneca in a research report on Friday. Finally, Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Astrazeneca in a report on Tuesday, June 9th. Twelve investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Astrazeneca currently has an average rating of “Moderate Buy” and an average target price of $205.33.

Astrazeneca Stock Performance

Shares of NYSE AZN opened at $188.58 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. Astrazeneca Plc has a one year low of $137.23 and a one year high of $212.71. The business’s 50-day moving average price is $184.66 and its two-hundred day moving average price is $187.05. The company has a market capitalization of $292.47 billion, a P/E ratio of 28.32, a price-to-earnings-growth ratio of 1.64 and a beta of 0.25.

Astrazeneca (NYSE:AZN) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The business had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. Analysts anticipate that Astrazeneca Plc will post 9.39 earnings per share for the current fiscal year.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.